The European Society for Medical Oncology (ESMO) has broadened its recommendations for the use of next-generation sequencing (NGS) in patients with advanced cancers. The updated guidelines now include patients with advanced breast cancer, rare tumors such as GIST, sarcoma, thyroid cancer, and cancer of unknown primary origin. This expansion is based on the increasing understanding of the molecular landscape of these cancers and the significant potential for improving patient outcomes through targeted therapies.
Key recommendations include performing tumor NGS in clinical research settings and specific circumstances discussed with patients, especially in countries where tumor-agnostic targeted therapies are accessible. The inclusion of tumor NGS can facilitate personalized treatment plans and potentially lead to better clinical outcomes.
Surgeons and oncologists should consider integrating these new recommendations into their practice to stay aligned with the latest advancements in precision medicine. The cost-effectiveness and local implementation of NGS should be evaluated to ensure optimal integration into clinical workflows.
URL: 10.1016/j.annonc.2024.04.005
Leave a Reply